Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499

Eli Lilly And Co (NYSE:LLY) announced on Monday that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—would soon be available in single-dose vials for $499 per month through LillyDirect’s Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey…

This story appeared on benzinga.com, 2025-06-16 12:53:40.
The Entire Business World on a Single Page. Free to Use →